Survival and late mortality among patients who survived disease‐free for 2 years after stem cell transplantation

Most events that limit life expectancy after allogeneic haematopoietic stem cell transplantation (allo-HSCT) occur within the first 2 years; however, treatment outcomes in long-term survivors who survive for at least 2 years post-HSCT without relapse are yet to be elucidated. To explore the life expectancy trends and late complications and to assess the main mortality-related factors, we investigated the characteristics of patients who received allo-HSCT for haematological malignancies from 2007 to 2019 in our centre and survived in remission for 2 years. A cohort of 831 patients was enrolled; of these, 508 received grafts from haploidentical-related donors (61.1%). The estimated overall survival rate at 10 years was 91.9% (95% confidence interval [CI], 89.8-93.5), which was affected by prior grade III-IV acute graft-versus-host disease (GVHD) (hazard ratio [HR], 2.98; 95% CI, 1.47-6.03; p = 0.002) and severe chronic GVHD (HR, 3.60; 95% CI, 1.93-6.71; p < 0.001). The probability of late relapse and non-relapse mortality at 10 years was 8.7% (95% CI, 6.9-10.8) and 3.6% (95% CI, 2.5-5.1) respectively. The top cause of late mortality was relapsed (49.0%). Projected long-term survival in 2-year disease-free survivors following allo-HSCT was excellent. Strategies should be implemented to minimise the late death-specific hazards in recipients.

[1]  M. Robin,et al.  Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation , 2022, Bone Marrow Transplantation.

[2]  He Huang,et al.  Effect of donor characteristics on T cell‐replete haploidentical stem cell transplantation over the last 10 years at a single institution , 2021, British journal of haematology.

[3]  J. Pidala,et al.  Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis. , 2021, Transplantation and cellular therapy.

[4]  J. Hicks,et al.  Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades: A Blood or Marrow Transplant Survivor Study Report. , 2021, JAMA oncology.

[5]  N. Kröger,et al.  One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors , 2021, Haematologica.

[6]  S. Steinberg,et al.  Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease. , 2021, Transplantation and cellular therapy.

[7]  D. Rizzieri,et al.  Female Sex is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant. , 2021, Transplantation and cellular therapy.

[8]  I. Kerridge,et al.  Hematopoietic stem cell transplant recipients surviving at least 2 years from transplant have survival rates approaching population levels in the modern era of transplantation. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  He Huang,et al.  Antithymocyte globulin improves GVHD-free and relapse-free survival in unrelated hematopoietic stem cell transplantation , 2019, Bone Marrow Transplantation.

[10]  M. Labopin,et al.  Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients , 2019, JAMA oncology.

[11]  M. Tucker,et al.  Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. , 2018, Journal of the American Academy of Dermatology.

[12]  M. Solh,et al.  Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients , 2018, Bone Marrow Transplantation.

[13]  S. Bhatia,et al.  How I monitor long-term and late effects after blood or marrow transplantation. , 2017, Blood.

[14]  A. Barrett,et al.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  Stephanie J. Lee,et al.  Late effects of blood and marrow transplantation , 2017, Haematologica.

[16]  E. Holler,et al.  Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  L. Ashton,et al.  Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Population-Based Cohort Study. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  He Huang,et al.  T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. , 2014, Blood.

[19]  M. Horowitz,et al.  Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. , 2014, Blood.

[20]  K. Kawa,et al.  Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Yu-Hong Chen,et al.  Long‐term follow‐up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia , 2013, Cancer.

[22]  H. Nakasone,et al.  Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  B. Esterni,et al.  The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT , 2012, Bone Marrow Transplantation.

[24]  S. Bhatia,et al.  Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). , 2011, Blood.

[25]  H. Einsele,et al.  Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. , 2011, Blood.

[26]  R. Storb,et al.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.

[27]  A. Barrett,et al.  Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  J. Wingard,et al.  Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. , 2010, Blood.

[29]  J. Simpson,et al.  Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  J. Fay,et al.  Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. , 2009, Blood.

[31]  H. Deeg,et al.  Solid cancers after allogeneic hematopoietic cell transplantation. , 2009, Blood.

[32]  J. Wagner,et al.  A scheme for defining cause of death and its application in the T cell depletion trial. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  A. Nademanee,et al.  Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. , 2007, Blood.

[34]  M. Mohty,et al.  Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond , 2007, Leukemia.

[35]  F. Aversa,et al.  Competing risk analysis using R: an easy guide for clinicians , 2007, Bone Marrow Transplantation.

[36]  Y. Kodera,et al.  Chronic graft‐versus‐host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program , 2007, British journal of haematology.

[37]  P. Bruzzi,et al.  Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[38]  G. Pond,et al.  Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[39]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  Je-Hwan Lee,et al.  Graft‐versus‐host disease (GVHD)‐specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation , 2003, British journal of haematology.

[41]  M. Flowers,et al.  Chronic graft-versus-host disease. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[43]  P. Ljungman,et al.  Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis , 1998, Bone Marrow Transplantation.

[44]  R. Hoover,et al.  Solid cancers after bone marrow transplantation. , 1997, The New England journal of medicine.

[45]  R. Bouabdallah,et al.  Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[46]  D. Porter,et al.  International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.